Available immediately through June 30, 2021, gain subsidized access to easy NGS through the GlobalAccess Sequencing Program. Designed to accelerate multi-institutional-led studies focused on SARS-CoV-2 research, this program will also support labs facing significant constraints as a result of the global crisis by offering faster access to comprehensive molecular profiling.
Our latest sequencing innovation, the Ion Torrent Genexus System, is primed for accomplishing what is needed now—fast, real-time acquisition of sequencing data with unprecedented automation that enables greater lab efficiency—all at a subsidized price.
Ion AmpliSeq SARS-CoV-2 Research Panel on the Genexus System
Rapid, accurate, and automated targeted NGS solution for SARS-CoV-2 epidemiology mapping and transmission studies. Go from nucleic acid to variant report in under a single day with minimal hands-on time.
Oncomine Precision Assay on the Genexus System
Next-generation genomic profiling solution that can allow every laboratory to deliver a genomic profile with a one-day, hands-free workflow. Detect mutation, CNV, and fusion variant types across 50 key genes.
The GlobalAccess Sequencing Program is open to all applications in the field of oncology research, all research consortia conducting collaborative, multi-institutional SARS-CoV-2-related studies, and national funded health programs, including those conducted by university and other academic labs, hospitals, public health laboratories, government agencies, and industrial partners.
Take advantage of this offer now. Complete the form below and a sales representative will contact you regarding a quote for the GlobalAccess Sequencing Program.
For Research Use Only. Not for use in diagnostic procedures.
